ePT--the Electronic Newsletter of Pharmaceutical Technology
A recent report conducted by The Department of Health and Human Services, Office of the Inspector General is stirring some concern over how the US Food and Drug Administration conducts inspections of clinical trials.
Washington, DC (Sept. 28)-A recent report conducted by the Department of Health and Human Services Office of the Inspector General (OIG) is stirring some concern over how the US Food and Drug Administration conducts inspections of clinical trials. Specifically the report, entitled “The Food and Drug Administration’s Oversight of Clinical Trials,” focuses on the agency’s bioresearch monitoring (BiMo) program between 2000 and 2005.
OIG estimates that FDA inspected only 1% of clinical trial sites during these five years.
The report states that FDA “is unable to identify all ongoing clinical trials and their associated trial sites.” This mismanagement of the BiMo program is a direct result of the lack of a complete clinical trial registry and the Office of Regulatory Affairs’s database “does not include complete information for inspection events that occur after it completes its inspection.”
The report also claims that the agency’s Centers also inconsistently classify “official action indicated” and “voluntary action indicated.” “FDA relies on voluntary compliance to correct violations of regulatory significance,” says the report. “Uncertainty of timing and lack of coordination impede FDA’s ability to conduct BiMo inspections.”
FDA reviewed the report and reports agreement to improve the program, including the development of an institutional review board registry. A copy of the report is available here.
Sen. Chuck Grassley (R-IA) wrote a letter to FDA Commissioner Andrew von Eschenbach requesting a meeting to discuss the OIG report. Grassley addressed his concerns about the OIG's findings, and asked FDA to arrange a meeting by Nov. 5 with the Senate Findings Committee. A copy of Grassley's letter is available here.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.